Balyasny Asset Management
XENE icon

Balyasny Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Balyasny Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Sell
193,407
-40,498
-17% -$2.25M 0.01% 989
2026
Q1 		$13.6M Buy
233,905
+149,545
+177% +$6.89M 0.02% 871
2025
Q4 		$3.78M Sell
84,360
-238,096
-74% -$10M ﹤0.01% 1535
2025
Q3 		$12.9M Buy
322,456
+253,587
+368% +$8.93M 0.02% 924
2025
Q2 		$2.16M Sell
68,869
-198,273
-74% -$6.47M ﹤0.01% 1691
2025
Q1 		$8.96M Buy
267,142
+82,562
+45% +$3.13M 0.01% 977
2024
Q4 		$7.24M Buy
184,580
+100,382
+119% +$4.15M 0.01% 1108
2024
Q3 		$3.31M Sell
84,198
-149,137
-64% -$6.01M 0.01% 1447
2024
Q2 		$9.1M Buy
233,335
+32,061
+16% +$1.28M 0.02% 926
2024
Q1 		$8.66M Buy
201,274
+185,423
+1,170% +$8.53M 0.02% 993
2023
Q4 		$730K Buy
+15,851
New +$560K ﹤0.01% 1810
2023
Q1 		– Sell
-162,828
Closed -$6.42M – 3221
2022
Q4 		$6.42M Buy
162,828
+15,473
+11% +$563K 0.02% 921
2022
Q3 		$5.32M Buy
+147,355
New +$5.3M 0.02% 958

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Balyasny Asset Management's XENE Position: Q2 2026 in Review

Balyasny Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 17% in Q2 2026, selling an estimated $2.25M and leaving 193,407 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #989.

Balyasny Asset Management first reported a position in XENE in Q3 2022 and has held it in 13 quarters since. The position peaked at $13.6M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Balyasny Asset Management held 193,407 shares of Xenon Pharmaceuticals worth $11.7M as of Q2 2026.
  • Balyasny Asset Management sold 40,498 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • Xenon Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #989 holding.
  • Balyasny Asset Management first reported a position in Xenon Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • Balyasny Asset Management's Xenon Pharmaceuticals position peaked at $13.6M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.